Splice sensors for cancer drug discovery - SUMMARY:
Targeting pyruvate kinase remains a challenge in cancer drug discovery. Despite compelling evidence
highlighting the importance of the pyruvate kinase isoform M2 (PKM2) in cancer cell growth and proliferation,
drug discovery efforts targeting the glycolytic activities of PKM2 have yet to yield a successful drug candidate for
clinical use. Discovery efforts that are focused on developing chemical compounds that keep PKM2 arrested in
an active (activators) or inactive state (inhibitors), are either mired in potency or specificity issues, or have left
the non-glycolytic tumorigenic activity of PKM2 largely untouched. There is a critical need for drugs that can
block both the glycolytic and non-glycolytic activities of PKM2. Recent evidence has shown that various
heteronuclear RNA binding proteins (hnRNPs) and splicing factors are involved in formation of the PKM2 isoform
in cancer cells. A novel approach to target cancer cells is to suppress PKM2 mRNA splicing in favor of splicing
that leads to the non-oncogenic PKM1 isoform. Although this would prevent both glycolytic and non-glycolytic
functions of PKM2, discovery efforts targeting PKM2 splicing are non-existent. This paucity is due to lack of good
splice sensing platform technologies that are fast, simple, and HTS compatible. The currently available methods
are slow, laborious, or complicated. Moreover, they do not allow direct monitoring of endogenously spliced
mRNA that forms in cells. Here, we propose a robust, HTS compatible, mix-and-read splice sensor assay that
is based on a proven “Spinach” fluorescence biosensor technology. This splice sensor would allow direct
monitoring of endogenous PKM2 mRNA levels in in vitro cell-based experiments. The splice sensor will produce
fluorescence proportional to the amount of PKM2 mRNA in cells and not be affected by other interfering mRNA
such as PKM1 or the PKM pre-mRNA. Prototype PKM1 and PKM2 splice sensors developed by Lucerna
scientists have demonstrated the feasibility of this concept, established its specificity, and confirmed that it is
tunable. In this project, we will additionally construct PKM-based sensors that allow simultaneous (multiplexed)
monitoring of PKM1 and PKM2 RNA in the same sample. We will optimize both the prototype sensors and the
multiplexed sensors for HTS and develop assay conditions such that they exhibit high fluorescence, sensitivity,
specificity and broad dynamic range while showing minimal background signal. More importantly, this new HTS
compatible method will work directly on cell lysates and enable researchers for the first time to measure the
endogenous PKM2 mRNA levels in a fast, and reliable way. At the end of this phase I project, we will
commercialize this splice sensor as assay kits. In the next phase of the project, we will validate the splice sensor
assay for HTS-based drug discovery by performing a pilot validation drug screen. The HTS adaptation of the in
vitro cell-based splice sensor assay will enable the pharmaceutical industry to develop new drugs that block the
PKM2 glycolytic and non-glycolytic tumorigenic activities. Lastly, we will leverage the splice sensor platform to
develop a suite of assays that would enable the pharmacologic targeting of aberrant splicing in other diseases.
